Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s second patent family has obtained patents in Israel and in Malaysia, respectively. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“The development of our lead drug candidate CS1 is currently progressing in a Phase II study with active patient recruitment across sites in the US. I am pleased to, in parallel, have news related to CS1’s growing patent portfolio